Cellectis(NASDAQ) CLLS

Cellectis S.A. is a biotechnology firm focused on developing innovative immuno-oncology therapies. The company specializes in gene-edited T-cells designed to target and eliminate cancerous cells, with a robust pipeline of product candidates in clinical development.

Products and Services

• UCART19: Allogeneic T-cell therapy for blood cancers
• ALLO-501 and ALLO-501A: Targeting diffuse large B-cell lymphoma
• Strategic partnerships with leading biotech firms and research institutions

Growth Outlook

• Strong pipeline with multiple candidates in clinical trials
• Recent partnerships enhance research capabilities and market reach
• Focus on expanding therapeutic applications in oncology

Financial Highlights

• Q2 2026 revenue of $5.23 million, showing consistent growth
• Trailing twelve months (TTM) gross profit margin at 74.68%
• Cash and short-term investments totaling $166.85 million as of Q2 2026

Cellectis S.A. operates in a dynamic sector with significant potential for growth. The company's focus on gene-edited therapies positions it well within the biotechnology landscape, particularly in the immuno-oncology space. The diverse product pipeline, including therapies targeting various blood cancers, reflects a commitment to addressing unmet medical needs. Recent financial performance indicates a steady revenue stream, bolstered by a strong gross profit margin, which is critical for sustaining research and development efforts. The substantial cash reserves provide a solid foundation for future initiatives and partnerships, enhancing the company's ability to innovate and expand its market presence.